Biovie Inc. (BIVI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Biovie reported revenue of $0. Net income was -$22.1M, or -$3.05 per diluted share. Operating activities generated -$19.0M of cash. At fiscal year end, Biovie held $14.3M in total assets against $4.0M in total liabilities, including $9.0M of cash and equivalents.
Open the full interactive Biovie financials → Quarterly statements, key ratios, valuation history and price charts.
Biovie Key Stats
| Share Price | $1.20 |
|---|---|
| Market Cap | $8.7M |
| 52-Week Range | $0.96 – $2.28 |
| Shares Outstanding | 7.2 million (basic, 2026 Q4) |
Biovie Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$138.1M | -$27.3M | -$45.1M | -$32.2M | -$18.1M | -$22.7M |
| Pre-Tax Income | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
| Net Income | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
| Diluted EPS | -$1482.00 | -$106.00 | -$155.00 | -$73.00 | -$12.12 | -$3.05 |
Biovie Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.1M | -$6.1M | -$5.3M | -$5.6M |
| Diluted EPS | -$0.98 | -$0.77 | -$0.70 | -$0.78 |
Biovie Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $19.5M | $23.8M | $17.5M | $9.0M |
| Current Assets | $4.6M | $18.8M | $34.0M | $24.0M | $20.7M | $13.6M |
| Total Assets | $6.0M | $20.1M | $35.1M | $25.2M | $21.6M | $14.3M |
| Current Liabilities | $996,374 | $4.2M | $14.5M | $9.4M | $2.3M | $3.8M |
| Total Long-Term Debt | — | $15.0M | $14.3M | $10.7M | — | — |
| Total Liabilities | $996,374 | $16.4M | $19.8M | $9.7M | $2.6M | $4.0M |
| Shareholders' Equity | $5.1M | $3.7M | $15.3M | $15.5M | $19.0M | $10.3M |
Biovie Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.5M | -$19.0M | -$40.3M | -$27.9M | -$19.0M | -$19.0M |
| Cash From Investing | — | — | -$14.3M | $14.5M | — | — |
| Cash From Financing | $14.9M | $33.1M | $55.4M | $17.8M | $12.7M | $10.5M |
Figures from Biovie's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biovie financials page for every line item.
Biovie Company Profile
| Ticker | BIVI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Carson City, Nevada |
| Incorporated in | Nevada |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001580149 |
Frequently Asked Questions
What was Biovie's revenue in fiscal 2026?
Biovie (BIVI) reported revenue of $0 for fiscal 2026.
What is Biovie's annual revenue history?
Biovie's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was Biovie's net income in fiscal 2026?
Biovie reported net income of -$22.1M for fiscal 2026.
What was Biovie's earnings per share (EPS) in fiscal 2026?
Biovie's diluted EPS was -$3.05 for fiscal 2026 (adjusted for any later stock splits).
What was Biovie's revenue last quarter?
In its most recent reported quarter (2026 Q4), Biovie reported revenue of $0.
How many shares of Biovie are outstanding?
Biovie reported a weighted average of 7.2 million basic shares outstanding in 2026 Q4.
What is Biovie's market cap?
Based on its latest closing price, Biovie (BIVI) has a market capitalization of about $8.7M.
When does Biovie's fiscal year end?
Biovie's fiscal year end, as registered with the SEC, is June 30.
Where is Biovie headquartered?
Biovie lists its business address in Carson City, Nevada in its SEC filings.